Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

53
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
53
Human Genetics01:28

Human Genetics

923
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
923
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

2.6K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.6K
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

3.5K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.5K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

40
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
40
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

14.8K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
14.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Area-Level Socioeconomic Deprivation on Post-PCI Outcomes Stratified by P2Y<sub>12</sub> Inhibitor Therapy.

JACC. Advances·2026
Same author

Characterizing Alzheimer's Disease and Related Dementia in a Hypertension Population Within the State of Florida Using Electronic Health Record-Based Data.

Clinical pharmacology and therapeutics·2025
Same author

CYP2D6 Phenotypes and Emergency Department Visits Among Patients Receiving Opioid Treatment.

JAMA network open·2025
Same author

Evaluating the Evidence for CYP2C19 Inhibitor Classifications: A Scoping Review.

Clinical pharmacology and therapeutics·2025
Same author

Use of electronic health records to characterize patients with uncontrolled hypertension in two large health system networks.

BMC cardiovascular disorders·2024
Same author

Characterizing apparent treatment resistant hypertension in the United States: insights from the All of Us Research Program.

Journal of the American Medical Informatics Association : JAMIA·2024
Same journal

Decoding Viral Dark Matter: Metagenomic Prokaryotic Virus Characterization With Pharokka, Phold, and Phynteny.

Current protocols·2026
Same journal

A Novel Laboratorial Approach to Evaluate Bacterial Microleakage of Endodontic Sealers.

Current protocols·2026
Same journal

TRIAGE Toolkit: Streamlined Discovery of Regulatory Genes and Elements.

Current protocols·2026
Same journal

High-throughput Profiling of Pseudouridines in Microbiome-derived Bacterial RNA.

Current protocols·2026
Same journal

Recombinant Protein Expression in Rhodococcus species.

Current protocols·2026
Same journal

Streamlined In Vitro Transcription for Generating Self-Amplifying RNA With Modified Nucleotides.

Current protocols·2026
See all related articles

Related Experiment Video

Updated: Oct 29, 2025

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
08:21

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

1.6K

Pharmacogenomics in Cardiovascular Diseases.

Caitrin W McDonough1

  • 1Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida.

Current Protocols
|July 7, 2021
PubMed
Summary
This summary is machine-generated.

Cardiovascular pharmacogenomics studies genomic markers impacting drug response and outcomes. This guide outlines designing studies for personalized cardiovascular medicine.

Keywords:
antihypertensive therapyantiplatelet therapycardiovascularcomplex diseasespharmacogenomics

More Related Videos

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

1.9K
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.1K

Related Experiment Videos

Last Updated: Oct 29, 2025

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
08:21

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

1.6K
In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

1.9K
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.1K

Area of Science:

  • Pharmacogenomics
  • Genetics
  • Cardiovascular Medicine

Background:

  • Cardiovascular pharmacogenomics investigates genetic influences on drug efficacy and safety.
  • Understanding genetic variability is key to optimizing cardiovascular drug therapy.

Purpose of the Study:

  • To provide a comprehensive protocol for designing cardiovascular pharmacogenomics studies.
  • To guide researchers in identifying genomic markers for cardiovascular drug response.

Main Methods:

  • Study design protocol development.
  • Phenotype construction strategies.
  • Replication and validation approaches.
  • Statistical analysis considerations.

Main Results:

  • Established a framework for cardiovascular pharmacogenomics study design.
  • Highlighted critical factors for successful study implementation.
  • Provided context for interpreting results in relation to cardiovascular drugs and diseases.

Conclusions:

  • Effective study design is crucial for advancing cardiovascular pharmacogenomics.
  • This protocol facilitates the identification of genetic markers for personalized cardiovascular pharmacotherapy.